Second-Line Treatment Landscape for Advanced HCC

 

35th Annual New Treatments in Chronic Liver Disease
Avatar

Systemic Therapies for HCC: What Does the Gastroenterologist Need to Know?

By 35th Annual New Treatments in Chronic Liver Disease FEATURING Catherine Frenette, Julio Gutierrez, Constantine J. Karvellas
By 35th Annual New Treatments in Chronic Liver Disease FEATURING Catherine Frenette, Julio Gutierrez, Constantine J. Karvellas
282 views
August 10, 2021
0 Comments
Login to view comments. Click here to Login
Second-Line Treatment Landscape for Advanced HCC
17:15
Lorenza Rimassa

2L Systemic Treatment Approaches for Advanced HCC

15:29
10th Annual Winship Cancer Institute Gastrointestinal Cancer Virtual Symposium

Sequencing Therapy in Hepatocellular Carcinoma: A Good Problem to Ha…

Feat. M. Akce
13:03
CECOG Academy

Updates on Cabozantinib in RCC, HCC, and Thyroid Cancers

Feat. B. Mrinakova
24:13
UChicago Medicine: Sixth Annual Updates in Digestive Diseases

Liver Transplantation for HCC: Role of AFP, Overview of Current &…

Feat. A. A. Pillai
33:00
35th Annual New Treatments in Chronic Liver Disease

Systemic Therapies for HCC: What Does the Gastroenterologist Need to…

Feat. C. Frenette, J. Gutierrez, C. J. Karvellas
07:19
Northwell Health

Cabozantinib in Patients With Advanced and Progressing Hepatocellula…

Feat. A. Levy
31:02
Scripps MD Anderson Cancer Center Clinical Hematology & Oncology 2022

Updates in Systemic Therapy for HCC

Feat. R. Finn
55:46
University of Colorado Cancer Center

UColorado Updates on Hepatocellular Carcinoma and Biliary Tract Canc…

Feat. L. Davis
09:02
ASCO 2022 Conference Coverage

ASCO 2022 Immunotherapy With Nivolumab After Progression on Lenvatin…

Feat. A. Rauthan
05:12
ASCO 2022 Conference Coverage

ASCO 2022 IMMUNIB Trial: A Single-Arm, Phase II Study Evaluating Saf…

Feat. A. Vogel
39
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 Immunotherapy With Nivolumab After Progr…

Feat. A. Rauthan
04:54
ASCO 2022 Conference Coverage

ASCO 2022 IMMUTACE - A Biomarker-Orientated Phase II, Single-Arm, Op…

Feat. A. Vogel
07:35
ASCO 2022 Conference Coverage

ASCO 2022 on an Open-Label, Multicenter, Randomized Phase II Study o…

Feat. A. Ruth He, F. Banovac
40
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on an Open-Label, Multicenter, Randomize…

Feat. A. Ruth He, F. Banovac
05:07
Icahn School of Medicine at Mount Sinai

TKI in the Management of Advanced HCC

Feat. A. Villanueva
03:33
ASCO 2022 Conference Coverage

ASCO 2022 Patient-Reported Outcomes From the Phase 3 HIMALAYA Study …

Feat. P. Galle
10:11
ASCO 2022 Conference Coverage

ASCO 2022 on Atezolizumab + Bevacizumab vs Lenvatinib or Sorafenib i…

Feat. M. Rimini